Here we report the first case in literature of a patient with HR+/HER2+ early-stage breast cancer experiencing a type I KS following paclitaxel infusion and the role of genomics to disentangle such a complex therapeutic scenario and re-define the oncological management. This evidence concerns the gene ERBB2 and breast carcinoma.